MCID: HRT032
MIFTS: 73

Heart Disease

Categories: Cardiovascular diseases, Genetic diseases, Respiratory diseases

Aliases & Classifications for Heart Disease

MalaCards integrated aliases for Heart Disease:

Name: Heart Disease 12 6 3 15
Congenital Heart Defects 12 29 6 43 3 15 63
Congenital Heart Disease 12 29 55 6 15 73
Heart Failure 55 6 43 63 73
Heart Diseases 55 43 44 73
Congenital Anomaly of Heart 12
Disease, Heart, Congenital 40
Congenital Heart Disorder 76
Heart Defects, Congenital 44
Heart Disease, Congenital 40
Congestive Heart Failure 73
Heart Defects Congenital 55
Congenital Heart Defect 12
Heart-Congenital Defect 12
Heart Malformation 12
Heart Defect 12

Classifications:



Summaries for Heart Disease

MedlinePlus : 43 If you're like most people, you think that heart disease is a problem for others. But heart disease is the number one killer in the U.S. It is also a major cause of disability. There are many different forms of heart disease. The most common cause of heart disease is narrowing or blockage of the coronary arteries, the blood vessels that supply blood to the heart itself. This is called coronary artery disease and happens slowly over time. It's the major reason people have heart attacks. Other kinds of heart problems may happen to the valves in the heart, or the heart may not pump well and cause heart failure. Some people are born with heart disease. You can help reduce your risk of heart disease by taking steps to control factors that put you at greater risk: Control your blood pressure Lower your cholesterol Don't smoke Get enough exercise NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Heart Disease, also known as congenital heart defects, is related to heart, malformation of and congestive heart failure, and has symptoms including tremor, angina pectoris and edema. An important gene associated with Heart Disease is GATA4 (GATA Binding Protein 4), and among its related pathways/superpathways are Cardiac conduction and Human Embryonic Stem Cell Pluripotency. The drugs Ranolazine and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are cardiovascular system and muscle

Disease Ontology : 12 A cardiovascular system disease that involves the heart.

CDC : 3 Enjoy the holiday season with healthy habits that lower heart disease risk.

PubMed Health : 63 About congenital heart defects: Congenital (kon-JEN-ih-tal) heart defects are problems with the heart's structure that are present at birth. These defects can involve:

Wikipedia : 76 A congenital heart defect (CHD), also known as a congenital heart anomaly or congenital heart disease,... more...

Related Diseases for Heart Disease

Diseases in the Heart Disease family:

Congenital Heart Defects, Multiple Types, 6 Congenital Heart Defects, Multiple Types, 3
Congenital Heart Defects, Multiple Types, 2 Congenital Heart Defects, Multiple Types, 4
Congenital Heart Defects, Multiple Types, 5

Diseases related to Heart Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1687)
# Related Disease Score Top Affiliating Genes
1 heart, malformation of 33.8 MYH6 TBX5
2 congestive heart failure 33.1 HOTAIR MYH6 NPPA NPPB
3 cardiac arrest 32.4 NPPB RYR2 SCN5A
4 patent ductus arteriosus 1 32.1 GATA4 NKX2-5 NPPB
5 hypoplastic left heart syndrome 32.1 MYH6 NKX2-5 NPPA NPPB
6 syncope 32.1 NPPA NPPB SCN5A
7 double outlet right ventricle 32.1 GATA4 NKX2-5 ZIC3
8 familial progressive cardiac conduction defect 32.1 NKX2-5 SCN5A
9 aortic valve disease 1 32.0 H19 NKX2-5 NPPB
10 pulmonary valve stenosis 32.0 GATA4 SCN5A
11 atrial standstill 1 31.6 MIR320A MYH6 NPPB SCN5A
12 dilated cardiomyopathy 31.5 GATA4 MIR196A2 MYH6 NKX2-5 NPPA NPPB
13 atrioventricular block 31.4 GATA4 NKX2-5 NPPB SCN5A TBX5
14 aortic valve disease 2 31.4 NPPA NPPB TBX5
15 tricuspid valve disease 31.3 NKX2-5 NPPB ZIC3
16 atrial fibrillation 31.3 NPPA NPPB RYR2 SCN5A TBX5
17 left ventricular noncompaction 31.2 MYH6 NKX2-5 RYR2 SCN5A
18 atrial standstill 31.0 NPPA SCN5A
19 tetralogy of fallot 30.8 GATA4 MKKS NKX2-5 NPPA NPPB TBX5
20 atrial heart septal defect 30.7 GATA4 MYH6 NKX2-5 TBX5
21 transposition of the great arteries 30.5 NKX2-5 ZIC3
22 patent foramen ovale 30.5 GATA4 MYH6 NKX2-5 TBX5
23 ventricular septal defect 30.4 GATA4 NKX2-5 NPPB TBX5 ZIC3
24 ebstein anomaly 30.4 GATA4 NKX2-5 NPPB
25 mitral valve insufficiency 30.3 NPPA NPPB TBX5
26 familial sick sinus syndrome 30.3 MYH6 SCN5A
27 pulmonary valve disease 30.3 GATA4 TBX5
28 central sleep apnea 30.1 NPPA NPPB
29 ventricular fibrillation, paroxysmal familial, 1 30.1 NKX2-5 RYR2 SCN5A
30 holt-oram syndrome 30.1 MYH6 NKX2-5 TBX5
31 atrioventricular septal defect 30.1 GATA4 NKX2-5 TBX5
32 third-degree atrioventricular block 29.9 NPPB SCN5A
33 heart septal defect 29.9 GATA4 NKX2-5 TBX5
34 deafness, congenital heart defects, and posterior embryotoxon 12.6
35 short stature, developmental delay, and congenital heart defects 12.5
36 coronary heart disease 1 12.5
37 multiple joint dislocations, short stature, and craniofacial dysmorphism with or without congenital heart defects 12.5
38 hypertensive heart disease 12.5
39 congenital heart defects, multiple types, 3 12.4
40 congenital heart defects, multiple types, 4 12.4
41 congenital heart defects, multiple types, 5 12.4
42 congenital heart defects, dysmorphic facial features, and intellectual developmental disorder 12.4
43 congenital heart defects and ectodermal dysplasia 12.4
44 congenital heart defects, multiple types, 6 12.4
45 congenital heart defects, hamartomas of tongue, and polysyndactyly 12.4
46 rheumatic heart disease 12.4
47 ischemic heart disease 12.3
48 cleft lip and palate-craniofacial dysmorphism-congenital heart defect-hearing loss syndrome 12.2
49 critical congenital heart disease 12.2
50 coronary heart disease 5 12.2

Comorbidity relations with Heart Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 320)


3-Hydroxyacyl-Coa Dehydrogenase Deficiency Accessory Nerve Disease
Acquired Polycythemia Acquired Thrombocytopenia
Active Peptic Ulcer Disease Acute Anterolateral Myocardial Infarction
Acute Apical Periodontitis Acute Conjunctivitis
Acute Cor Pulmonale Acute Cystitis
Acute Inferolateral Myocardial Infarction Acute Kidney Failure
Acute Maxillary Sinusitis Acute Myocardial Infarction
Acute Myocarditis Acute Pancreatitis
Acute Vascular Insufficiency of Intestine Adjustment Disorder
Age-Related Hearing Loss Alcoholic Cardiomyopathy
Alcoholic Liver Cirrhosis Allergic Urticaria
Alzheimer Disease Amyloidosis
Anemia, Autoimmune Hemolytic Anthracosis
Anxiety Aortic Aneurysm
Aortic Atherosclerosis Aortic Valve Disease 1
Aortic Valve Disease 2 Aortic Valve Insufficiency
Asbestosis Aspergillosis
Asthma Atrial Standstill 1
Atrioventricular Block Atrophic Gastritis
Bacteremia 2 Balanoposthitis
Basilar Artery Insufficiency Benign Essential Hypertension
Benign Hypertensive Renal Disease Benign Renovascular Hypertension
Bleeding Disorder, Platelet-Type, 11 Blepharitis
Blepharoconjunctivitis Bronchiectasis
Bronchitis Bronchopneumonia

Graphical network of the top 20 diseases related to Heart Disease:



Diseases related to Heart Disease

Symptoms & Phenotypes for Heart Disease

UMLS symptoms related to Heart Disease:


tremor, angina pectoris, edema, chest pain, syncope, equilibration disorder

MGI Mouse Phenotypes related to Heart Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.65 ABL1 GATA4 MKKS MYH6 NKX2-5 NPPA
2 muscle MP:0005369 9.23 ABL1 GATA4 MYH6 NKX2-5 NPPA RYR2

Drugs & Therapeutics for Heart Disease

PubMedHealth treatment related to Heart Disease: 63

Although many children who have congenital heart defects don't need treatment, some do. Doctors repair congenital heart defects with catheter procedures or surgery.Sometimes doctors combine catheter and surgical procedures to repair complex heart defects, which may involve several kinds of defects.The treatment your child receives depends on the type and severity of his or her heart defect. Other factors include your child's age, size, and general health.Some children who have complex congenital heart defects may need several catheter or surgical procedures over a period of years, or they may need to take medicines for years.

Drugs for Heart Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1194)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranolazine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 142387-99-3, 95635-55-5 56959
2
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
3
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113665-84-2, 120202-66-6 60606
4
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
5
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55142-85-3 5472
6
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
7
Cilostazol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 73963-72-1 2754
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
9
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
10
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2 128270-60-0 16129704
11
Fluvastatin Approved Phase 4,Phase 3,Phase 2 93957-54-1 1548972
12
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 72956-09-3 2585
13
Clonidine Approved Phase 4,Not Applicable 4205-90-7 2803
14
Sevoflurane Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 28523-86-6 5206
15 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 113775-47-6 68602 5311068
17
Hydromorphone Approved, Illicit Phase 4,Phase 2 466-99-9 5284570
18
Ropivacaine Approved Phase 4,Phase 2,Not Applicable 84057-95-4 175805 71273
19
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
20
Sufentanil Approved, Investigational Phase 4,Phase 2,Not Applicable 56030-54-7 41693
21
Etomidate Approved Phase 4,Phase 2 33125-97-2 667484 36339
22
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
23
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 274693-27-5 9871419
24
Nicorandil Approved, Investigational Phase 4,Not Applicable 65141-46-0 47528
25
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
26
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
27
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137862-53-4 60846
28
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
29
Nicotinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 98-92-0 936
30
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6
31
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
32
Sotalol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 959-24-0, 3930-20-9 5253
33
Amiodarone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1951-25-3 2157
34
Verapamil Approved Phase 4,Phase 2,Phase 3,Not Applicable 52-53-9 2520
35
Cobalt Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 7440-48-4 104729
36
Chromium Approved Phase 4,Phase 3,Not Applicable 7440-47-3 27668
37
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
38
Pantoprazole Approved Phase 4,Phase 3,Phase 1 102625-70-7 4679
39
Esomeprazole Approved, Investigational Phase 4,Phase 2 161796-78-7, 119141-88-7 4594 9579578
40
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
41
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 28014-46-2
42
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 2,Phase 3 71-58-9
43
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 57-83-0 5994
44 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 979-32-8
45
Exenatide Approved, Investigational Phase 4,Phase 3,Not Applicable 141758-74-9 15991534
46
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
47
Ethinyl Estradiol Approved Phase 4,Phase 1,Not Applicable 57-63-6 5991
48
Citalopram Approved Phase 4,Not Applicable 59729-33-8 2771
49
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 163222-33-1 150311
50
Irbesartan Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 138402-11-6 3749

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist Unknown status NCT00668824 Phase 4 Vasovist
2 Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
3 The Effect of Tongguan Capsule for MicroRNA Profiles in Coronary Heart Disease Patients Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
4 Ranolazine for Improving Symptoms of Palpitations Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
5 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
6 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
7 Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI Unknown status NCT02787317 Phase 4 bivalirudin;Heparin
8 Endothelial Dysfunction in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
9 Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
10 Fluvastatin AmelIorates aTHerosclerosis Study Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
11 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Unknown status NCT01382277 Phase 4 Rosuvastatin
12 Diagnostic Benefits of HyperQTM vs. Conventional ECG Stress Test. Comparison of HyperQ vs. Stress ECG in Women Before Angiography Unknown status NCT00850486 Phase 4
13 Hemoderivative Imputable Complications in Initial Uncomplicated Heart Surgery Unknown status NCT01457586 Phase 4
14 Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
15 EPIC (Evaluating Perioperative Ischemia Reduction by Clonidine) Unknown status NCT00335582 Phase 4 clonidine hydrochloride
16 Different Dosage of Domestic and Imported Clopidogrel on the Platelet Inhibition Ratio in Patients Undergoing PCI Unknown status NCT03006835 Phase 4 Clopidogrel
17 Studies of Application of Combined General Anesthesia and Bilateral TPVB in OPCABG Unknown status NCT02727712 Phase 4 Anesthesia drugs during the surgery
18 Relation Among Shear Stress Distribution, Stent Design, and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES) Unknown status NCT01942044 Phase 4
19 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for DES Surface COVERage by OCT Unknown status NCT01021930 Phase 4
20 Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing Unknown status NCT01456364 Phase 4 Ticagrelor;Prasugrel
21 Test of Long-Term Safety and Efficacy of Sirolimus-Permanent-Polymer Eluting Stent (Cypher)- and Sirolimus-Polymer-free Eluting Stents (PPS/PFS) Assessed by Optical Coherence Tomography Unknown status NCT01260558 Phase 4
22 Test Safety and Efficacy of Zotarolimus- and Everolimus-Eluting Stents (ZES/EES) Assessed by Optical Coherence Tomography Unknown status NCT01230723 Phase 4
23 Test Efficacy of Biodegradable and Permanent Limus-Eluting Stents Unknown status NCT01068106 Phase 4
24 Effect of Nicorandil for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4 Nicorandil;normal saline
25 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4 quinipril
26 Enteral Nutrition After Cardiovascular Surgery Unknown status NCT01432769 Phase 4
27 Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial) Unknown status NCT00858676 Phase 4 acarbose
28 Metformin in Postmenopausal Women With Metabolic Syndrome Unknown status NCT01342744 Phase 4 Metformin;Placebo
29 Effect of Rosuvastatin Therapy on HDL2 Level Unknown status NCT02593487 Phase 4 Rosuvastatin 10mg/d group;Rosuvastatin 20mg/d group
30 The ABC Trial Does All-Blood Cardioplegia Prevent Blood Transfusion in Cardiac Surgery? A Single Centre Pilot Study Unknown status NCT01623193 Phase 4
31 Comparison of Biolimus A9 and Everolimus Drug-Eluting Stents in Patients With ST Segment Elevation Myocardial Infarction Unknown status NCT00888758 Phase 4
32 Revascularization in Heart Failure Trial – REHEAT 2 Unknown status NCT00388245 Phase 4
33 Effect of Ranolazine on Valvular Disease in Patients With Pacemakers Unknown status NCT01979965 Phase 4 Ranolazine (Active drug);Placebo
34 A Morbidity-Mortality and Remodeling Study With Valsartan Unknown status NCT00133328 Phase 4 valsartan
35 Patent Versus Generic Clopidogrel in Acute Coronary Syndrome Unknown status NCT02628587 Phase 4 Generic clopidogrel;Patent clopidogrel
36 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients Unknown status NCT01503671 Phase 4 Atorvastatin
37 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
38 Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP Unknown status NCT00584350 Phase 4
39 Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Unknown status NCT00155350 Phase 4 pioglitazone
40 Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Ischemic Ventricular Tachyarrhythmias Unknown status NCT02303639 Phase 4 Antiarrhythmic drug therapy
41 Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
42 Therapy With Verapamil or Carvedilol in Chronic Heart Failure Unknown status NCT00374465 Phase 4 Verapamil;Carvedilol
43 Rosuvastatin Effect on Telomere-telomerase System in ACS Unknown status NCT02299245 Phase 4 rosuvastatin
44 Does Sildenafil Protect Against Pulmonary Related Complications Following Cardiopulmonary Bypass? Unknown status NCT00350441 Phase 4 Sildenafil Citrate
45 Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
46 Comparative Phase IV Study: Efficacy And Safety of TiTAN2 Versus COBALT-CHROME Stents- EVIDENCEII Unknown status NCT01918150 Phase 4
47 Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP & Platelet Mapping ™ Assay Unknown status NCT01023360 Phase 4 Clopidogrel and proton pump inhibitors
48 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
49 Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside) Unknown status NCT00963781 Phase 4 Reduced duration (6 months) DAPT
50 Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function Unknown status NCT02584075 Phase 4 Byetta (Exenatide);Glucophage ( Metformin Hydrochloride)

Search NIH Clinical Center for Heart Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: heart diseases

Genetic Tests for Heart Disease

Genetic tests related to Heart Disease:

# Genetic test Affiliating Genes
1 Congenital Heart Disease 29
2 Congenital Heart Defects 29

Anatomical Context for Heart Disease

MalaCards organs/tissues related to Heart Disease:

41
Heart, Testes, Endothelial, Brain, Kidney, Lung, Bone

Publications for Heart Disease

Articles related to Heart Disease:

(show top 50) (show all 10179)
# Title Authors Year
1
Adults with congenital heart disease overestimate their physical activity level. ( 30480085 )
2019
2
Chromosome 12q24.31 microdeletion and congenital heart disease: a case report and review of the literature. ( 30507726 )
2019
3
Geographical variation and predictors of physical activity level in adults with congenital heart disease. ( 30511012 )
2019
4
EDUCATIONAL SERIES IN CONGENITAL HEART DISEASE: Tetralogy of Fallot: diagnosis to long-term follow-up. ( 30557849 )
2019
5
Hemodynamics of the diastolic pressure gradients in acute heart failure: implications for the diagnosis of pre-capillary pulmonary hypertension in left heart disease. ( 30419797 )
2019
6
Contemporaneous management of valvular heart disease and aortopathy in aircrew. ( 30425087 )
2019
7
Congenital heart disease in aircrew. ( 30425088 )
2019
8
Letter regarding Groves et al. "Feasibility of low radiation dose retrospectively-gated cardiac CT for functional analysis in adult congenital heart disease". ( 30449336 )
2019
9
Valvular Heart Disease and Heart Failure in Women. ( 30449382 )
2019
10
Heart Failure in Women with Congenital Heart Disease. ( 30449383 )
2019
11
Transcatheter Pulmonary Valve Replacement in Congenital Heart Disease. ( 30449422 )
2019
12
Biodegradable Stents for Congenital Heart Disease. ( 30449424 )
2019
13
Computed Tomography in Adult Congenital Heart Disease. ( 30454820 )
2019
14
The impact of trisomy 21 on treatment modalities and outcome in adults with congenital heart disease in Switzerland. ( 30338722 )
2019
15
Aortic dissection and prophylactic surgery in congenital heart disease. ( 30266350 )
2019
16
Myocardial perfusion assessed with cardiac computed tomography in women without coronary heart disease. ( 30270499 )
2019
17
Self-reported myocardial infarction and fatal coronary heart disease among oil spill workers and community members 5 years after Deepwater Horizon. ( 30278364 )
2019
18
Relationship Between Types of Social Support, Coping Strategies, and Psychological Distress in Individuals Living With Congenital Heart Disease. ( 30303892 )
2019
19
Individualized Family-Centered Developmental Care: An Essential Model to Address the Unique Needs of Infants With Congenital Heart Disease. ( 30303895 )
2019
20
Dietary patterns, bone lead and incident coronary heart disease among middle-aged to elderly men. ( 30317107 )
2019
21
Low skeletal muscle mass is associated with low aerobic capacity and increased mortality risk in patients with coronary heart disease - a CARE CR study. ( 30168241 )
2019
22
Newborn screening for congenital heart disease using echocardiography and follow-up at high altitude in China. ( 30195837 )
2019
23
Pulmonary function in repaired congenital heart disease: Our attention must reach beyond the mended heart. ( 30209022 )
2019
24
Differences in Obesity Among Black and White Children, Adolescents, and Adults With Congenital Heart Disease. ( 30211814 )
2019
25
Risk of heart failure in a population with type 2 diabetes versus a population without diabetes with and without coronary heart disease. ( 30091215 )
2019
26
Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study. ( 30103277 )
2019
27
Depressive Symptoms in Women With Coronary Heart Disease: A Systematic Review of the Longitudinal Literature. ( 30138156 )
2019
28
Importance of structural heart disease and diastolic dysfunction in heart failure with preserved ejection fraction assessed according to the ESC guidelines - A substudy in the Ka (Karolinska) Ren (Rennes) study. ( 30049496 )
2019
29
Extracellular volume by cardiac magnetic resonance is associated with biomarkers of inflammation in hypertensive heart disease. ( 30063646 )
2019
30
Religion and spirituality as predictors of patient-reported outcomes in adults with congenital heart disease around the globe. ( 30077534 )
2019
31
Efficacy and adverse effects of sotalol in adults with congenital heart disease. ( 29954667 )
2019
32
Golden ratio stack of spirals for flexible angiographic imaging: Proof of concept in congenital heart disease. ( 29802643 )
2019
33
Appropriate Use Criteria for coronary revascularization in patients with stable ischemic heart disease: What the surgeon needs to know. ( 28606397 )
2019
34
Mechanical and structural analysis of the pulmonary valve in congenital heart defects: A presentation of two case studies. ( 30236979 )
2019
35
Psychosocial situation in adults with congenital heart defects today and 20 years ago: Any changes? ( 30336959 )
2019
36
Expression profile of maternal circulating microRNAs as non-invasive biomarkers for prenatal diagnosis of congenital heart defects. ( 30551536 )
2019
37
Increased left ventricular mass index is present in patients with type 2 diabetes without ischemic heart disease. ( 29343820 )
2018
38
Coagulation Factors in Ischemic Heart Disease: Answers From a Mendelian Randomization Study Inspire Further Questions. ( 29874185 )
2018
39
Management of radiation-induced valvular heart disease due to Hodgkin's Lymphoma in the modern era. ( 29131805 )
2018
40
Survival and Associated Risk Factors for Mortality Among Infants with Critical Congenital Heart Disease in a Developing Country. ( 29756159 )
2018
41
Perioperative neonatal brain injury is associated with worse school-age neurodevelopment in children with critical congenital heart disease. ( 29572821 )
2018
42
The role of social determinants of health in the risk and prevention of group A streptococcal infection, acute rheumatic fever and rheumatic heart disease: A systematic review. ( 29897915 )
2018
43
A Modified Algorithm for Critical Congenital Heart Disease Screening Using Pulse Oximetry. ( 29691284 )
2018
44
Human cytomegalovirus infection and coronary heart disease: a systematic review. ( 29409508 )
2018
45
Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited. ( 29948832 )
2018
46
Validation of acute kidney injury according to the modified KDIGO criteria in infants after cardiac surgery for congenital heart disease. ( 29451341 )
2018
47
Out-of-Hospital Cardiac Arrest in the Presence of Ischemic Heart Disease: What Is the Long-term Arrhythmic Risk After Revascularization? ( 29958725 )
2018
48
Diagnosis and treatment of postoperative intestinal perforation in infants and young children with congenital heart disease: A report of three cases. ( 29731834 )
2018
49
Outcomes for patients with rheumatic heart disease after cardiac surgery followed at rural district hospitals in Rwanda. ( 29678896 )
2018
50
A Hybrid Model for Advanced Structural Heart Disease Training Programs: The Attending-Fellow-in-Training Model. ( 29447743 )
2018

Variations for Heart Disease

ClinVar genetic disease variations for Heart Disease:

6 (show top 50) (show all 76)
# Gene Variation Type Significance SNP ID Assembly Location
1 NKX2-5 NM_004387.3(NKX2-5): c.73C> T (p.Arg25Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs28936670 GRCh37 Chromosome 5, 172662014: 172662014
2 NKX2-5 NM_004387.3(NKX2-5): c.73C> T (p.Arg25Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs28936670 GRCh38 Chromosome 5, 173235011: 173235011
3 NKX2-5 NM_004387.3(NKX2-5): c.61G> C (p.Glu21Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs104893904 GRCh37 Chromosome 5, 172662026: 172662026
4 NKX2-5 NM_004387.3(NKX2-5): c.61G> C (p.Glu21Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs104893904 GRCh38 Chromosome 5, 173235023: 173235023
5 PTCH1 NM_000264.4(PTCH1): c.2945G> A (p.Arg982Gln) single nucleotide variant Uncertain significance rs145924695 GRCh37 Chromosome 9, 98220518: 98220518
6 PTCH1 NM_000264.4(PTCH1): c.2945G> A (p.Arg982Gln) single nucleotide variant Uncertain significance rs145924695 GRCh38 Chromosome 9, 95458236: 95458236
7 MYH6 NM_002471.3(MYH6): c.2575G> T (p.Gly859Trp) single nucleotide variant Uncertain significance rs369274077 GRCh37 Chromosome 14, 23863387: 23863387
8 MYH6 NM_002471.3(MYH6): c.2575G> T (p.Gly859Trp) single nucleotide variant Uncertain significance rs369274077 GRCh38 Chromosome 14, 23394178: 23394178
9 NKX2-5 NM_004387.3(NKX2-5): c.443C> A (p.Ala148Glu) single nucleotide variant Pathogenic rs864321649 GRCh38 Chromosome 5, 173233101: 173233101
10 NKX2-5 NM_004387.3(NKX2-5): c.443C> A (p.Ala148Glu) single nucleotide variant Pathogenic rs864321649 GRCh37 Chromosome 5, 172660104: 172660104
11 NKX2-5 NM_004387.3(NKX2-5): c.391G> A (p.Glu131Lys) single nucleotide variant Pathogenic rs864321648 GRCh38 Chromosome 5, 173233153: 173233153
12 NKX2-5 NM_004387.3(NKX2-5): c.391G> A (p.Glu131Lys) single nucleotide variant Pathogenic rs864321648 GRCh37 Chromosome 5, 172660156: 172660156
13 NKX2-5 NM_004387.3(NKX2-5): c.335-1G> T single nucleotide variant Pathogenic rs864321645 GRCh38 Chromosome 5, 173233210: 173233210
14 NKX2-5 NM_004387.3(NKX2-5): c.335-1G> T single nucleotide variant Pathogenic rs864321645 GRCh37 Chromosome 5, 172660213: 172660213
15 NKX2-5 NM_004387.3(NKX2-5): c.335-12G> A single nucleotide variant Uncertain significance rs864321646 GRCh38 Chromosome 5, 173233221: 173233221
16 NKX2-5 NM_004387.3(NKX2-5): c.335-12G> A single nucleotide variant Uncertain significance rs864321646 GRCh37 Chromosome 5, 172660224: 172660224
17 NKX2-5 NM_004387.3(NKX2-5): c.335-20G> A single nucleotide variant Uncertain significance rs864321647 GRCh38 Chromosome 5, 173233229: 173233229
18 NKX2-5 NM_004387.3(NKX2-5): c.335-20G> A single nucleotide variant Uncertain significance rs864321647 GRCh37 Chromosome 5, 172660232: 172660232
19 NKX2-5 NM_004387.3(NKX2-5): c.182C> G (p.Ala61Gly) single nucleotide variant Pathogenic rs864321650 GRCh38 Chromosome 5, 173234902: 173234902
20 NKX2-5 NM_004387.3(NKX2-5): c.182C> G (p.Ala61Gly) single nucleotide variant Pathogenic rs864321650 GRCh37 Chromosome 5, 172661905: 172661905
21 GATA4 NM_002052.4(GATA4): c.23C> A (p.Ala8Asp) single nucleotide variant Pathogenic rs864321698 GRCh37 Chromosome 8, 11565844: 11565844
22 GATA4 NM_002052.4(GATA4): c.23C> A (p.Ala8Asp) single nucleotide variant Pathogenic rs864321698 GRCh38 Chromosome 8, 11708335: 11708335
23 GATA4 NM_002052.4(GATA4): c.25G> A (p.Ala9Thr) single nucleotide variant Pathogenic rs864321699 GRCh37 Chromosome 8, 11565846: 11565846
24 GATA4 NM_002052.4(GATA4): c.25G> A (p.Ala9Thr) single nucleotide variant Pathogenic rs864321699 GRCh38 Chromosome 8, 11708337: 11708337
25 GATA4 NM_002052.4(GATA4): c.27C> A (p.Ala9=) single nucleotide variant Pathogenic rs864321703 GRCh37 Chromosome 8, 11565848: 11565848
26 GATA4 NM_002052.4(GATA4): c.27C> A (p.Ala9=) single nucleotide variant Pathogenic rs864321703 GRCh38 Chromosome 8, 11708339: 11708339
27 GATA4 NM_002052.4(GATA4): c.383A> T (p.Glu128Val) single nucleotide variant Pathogenic rs864321700 GRCh37 Chromosome 8, 11566204: 11566204
28 GATA4 NM_002052.4(GATA4): c.383A> T (p.Glu128Val) single nucleotide variant Pathogenic rs864321700 GRCh38 Chromosome 8, 11708695: 11708695
29 GATA4 NM_002052.4(GATA4): c.397A> T (p.Ser133Cys) single nucleotide variant Pathogenic rs864321701 GRCh38 Chromosome 8, 11708709: 11708709
30 GATA4 NM_002052.4(GATA4): c.397A> T (p.Ser133Cys) single nucleotide variant Pathogenic rs864321701 GRCh37 Chromosome 8, 11566218: 11566218
31 GATA4 NM_002052.4(GATA4): c.682T> A (p.Trp228Arg) single nucleotide variant Pathogenic rs864321702 GRCh38 Chromosome 8, 11748984: 11748984
32 GATA4 NM_002052.4(GATA4): c.682T> A (p.Trp228Arg) single nucleotide variant Pathogenic rs864321702 GRCh37 Chromosome 8, 11606493: 11606493
33 GATA4 NM_002052.4(GATA4): c.997+2T> G single nucleotide variant Pathogenic rs864321705 GRCh37 Chromosome 8, 11612644: 11612644
34 GATA4 NM_002052.4(GATA4): c.997+2T> G single nucleotide variant Pathogenic rs864321705 GRCh38 Chromosome 8, 11755135: 11755135
35 GATA4 NM_002052.4(GATA4): c.1263C> T (p.Ser421=) single nucleotide variant Pathogenic rs864321704 GRCh38 Chromosome 8, 11758409: 11758409
36 GATA4 NM_002052.4(GATA4): c.1263C> T (p.Ser421=) single nucleotide variant Pathogenic rs864321704 GRCh37 Chromosome 8, 11615918: 11615918
37 GATA4 NM_002052.4(GATA4): c.997+56C> A single nucleotide variant Conflicting interpretations of pathogenicity rs804280 GRCh38 Chromosome 8, 11755189: 11755189
38 GATA4 NM_002052.4(GATA4): c.997+56C> A single nucleotide variant Conflicting interpretations of pathogenicity rs804280 GRCh37 Chromosome 8, 11612698: 11612698
39 GATA4 NM_002052.4(GATA4): c.909+25G> A single nucleotide variant Conflicting interpretations of pathogenicity rs147860174 GRCh38 Chromosome 8, 11750261: 11750261
40 GATA4 NM_002052.4(GATA4): c.909+25G> A single nucleotide variant Conflicting interpretations of pathogenicity rs147860174 GRCh37 Chromosome 8, 11607770: 11607770
41 RYR2 NM_001035.2(RYR2): c.6022+5G> A single nucleotide variant Uncertain significance rs376389213 GRCh38 Chromosome 1, 237623875: 237623875
42 RYR2 NM_001035.2(RYR2): c.6022+5G> A single nucleotide variant Uncertain significance rs376389213 GRCh37 Chromosome 1, 237787175: 237787175
43 ABL1 NM_007313.2(ABL1): c.1066G> A (p.Ala356Thr) single nucleotide variant Pathogenic rs1060499548 GRCh37 Chromosome 9, 133748348: 133748348
44 ABL1 NM_007313.2(ABL1): c.1066G> A (p.Ala356Thr) single nucleotide variant Pathogenic rs1060499548 GRCh38 Chromosome 9, 130872961: 130872961
45 ABL1 NM_007313.2(ABL1): c.734A> G (p.Tyr245Cys) single nucleotide variant Pathogenic rs1060499547 GRCh37 Chromosome 9, 133738277: 133738277
46 ABL1 NM_007313.2(ABL1): c.734A> G (p.Tyr245Cys) single nucleotide variant Pathogenic rs1060499547 GRCh38 Chromosome 9, 130862890: 130862890
47 GATA4 NM_002052.4(GATA4): c.617-116T> C single nucleotide variant Pathogenic rs3735819 GRCh38 Chromosome 8, 11748803: 11748803
48 GATA4 NM_002052.4(GATA4): c.617-116T> C single nucleotide variant Pathogenic rs3735819 GRCh37 Chromosome 8, 11606312: 11606312
49 GATA4 NM_002052.4(GATA4): c.617-64G> C single nucleotide variant Pathogenic rs10503425 GRCh37 Chromosome 8, 11606364: 11606364
50 GATA4 NM_002052.4(GATA4): c.617-64G> C single nucleotide variant Pathogenic rs10503425 GRCh38 Chromosome 8, 11748855: 11748855

Copy number variations for Heart Disease from CNVD:

7 (show top 50) (show all 60)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 17306 1 142400000 148000000 Duplication Heart disease
2 17316 1 142400000 148000000 Microdeletion Congenital heart defect
3 17332 1 142400000 148000000 Rearrangements Congenital heart defect
4 18950 1 148000000 149600000 Copy number Congenital heart defect
5 38769 10 104900000 105700000 Duplication CALHM1 Heart disease
6 38770 10 104900000 105700000 Duplication CALHM2 Heart disease
7 38771 10 104900000 105700000 Duplication PDCD11 Heart disease
8 40012 10 123100000 135374737 Deletion Heart disease
9 50206 11 115400000 134452384 Duplication Heart disease
10 65746 12 21200000 26300000 Deletion SLCO1A2 Heart disease
11 70609 12 63400000 66000000 Duplication Heart disease
12 81035 14 100400000 106368585 Deletion Congenital heart defect
13 83025 14 19100000 23600000 Duplication Heart disease
14 84174 14 23851199 23877482 Amplificationlicatio n MYH6 Congenital heart defects
15 86222 14 55800000 61200000 Duplication Heart disease
16 87066 14 69300000 72900000 Duplication Heart disease
17 92217 8 104452961 104464393 Duplication CTHRC1 Congenital heart defect
18 97907 16 14700000 16700000 Duplication or delet ion Congenital heart defects
19 106854 17 1 3600000 Duplication Heart disease
20 108227 17 19227347 19231086 Duplication MFAP4 Congenital heart defect
21 115120 17 54900000 58400000 Microdeletion TBX2 Heart disease
22 115122 17 54900000 58400000 Microdeletion TBX4 Heart disease
23 119183 18 1 2900000 Duplication Heart disease